Trial Outcomes & Findings for Intravenous Fat Emulsions and Premature Infants (NCT NCT01096446)

NCT ID: NCT01096446

Last Updated: 2014-11-20

Results Overview

Each day the infants have a serum triglyceride level drawn to assess their tolerance of the intravenous fat emulsion being given.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

19 participants

Primary outcome timeframe

First 7 days of life

Results posted on

2014-11-20

Participant Flow

Infants with a birthweight \< 750 grams were recruited from April 2008 through March 2010 at the neonatal intensive care unit at at the Children's Hospital of Illinois at OSF Saint Francis Medical Center Peoria, IL.

Thirty-five infants were deemed eligible for the study of which 13 infants were excluded due to one parent refused, 12 other infants were started on TPN prior to obtaining informed consent.

Participant milestones

Participant milestones
Measure
Higher Infusion
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Standard Infusion
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Overall Study
STARTED
12
10
Overall Study
COMPLETED
9
10
Overall Study
NOT COMPLETED
3
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Higher Infusion
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Standard Infusion
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Overall Study
Death
1
0
Overall Study
Protocol Violation
2
0

Baseline Characteristics

Intravenous Fat Emulsions and Premature Infants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard Infusion
n=10 Participants
Infants randomized into the experimental group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Higher Infusion
n=12 Participants
Infants randomized into the control group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Total
n=22 Participants
Total of all reporting groups
Age, Categorical
<=18 years
10 Participants
n=5 Participants
12 Participants
n=7 Participants
22 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
23.7 weeks
STANDARD_DEVIATION 0.68 • n=5 Participants
24.33 weeks
STANDARD_DEVIATION 1 • n=7 Participants
24 weeks
STANDARD_DEVIATION 0.5 • n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
9 Participants
n=7 Participants
14 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants
3 Participants
n=7 Participants
8 Participants
n=5 Participants
Region of Enrollment
United States
10 participants
n=5 Participants
12 participants
n=7 Participants
22 participants
n=5 Participants

PRIMARY outcome

Timeframe: First 7 days of life

Population: This study was ended early due to 100% of the infants in the experimental group developed hypertriglyceridemia of 200 mg/dl or greater

Each day the infants have a serum triglyceride level drawn to assess their tolerance of the intravenous fat emulsion being given.

Outcome measures

Outcome measures
Measure
Higher Infusion
n=9 Participants
Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Standard Infusion
n=10 Participants
Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
Number of Infants Serum Triglyceride Level Higher Than 200 mg/dl
9 participants
4 participants

SECONDARY outcome

Timeframe: First 2 weeks of life

Infants in both groups weights were monitored to determine if giving higher infusions of intravenous fat emulsion helped the infants regain their birthweight sooner.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: First 14 days of Life

Monitored the calorie intake of infants to see which group was able to acheive 90 cal/kg/day from the total parenteral nutrition.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Entire hospital stay

Recorded all infant's weights at discharge and plotted the anthropometric values on the Fenton Growth Charts.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: First 7 days of life

Infants were monitored to see if insulin was started to control hyperglycemia.

Outcome measures

Outcome data not reported

Adverse Events

Serum Triglycerides

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Kamlesh Macwan

OSF Saint Francis Medical Center

Phone: 309-624-0611

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place